Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.99
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.99
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.99
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€15.44
12.10.21
-
12.10.22
7.38%
16.10.21

Could be worthwhile Investment >10% per year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.60
04.10.21
-
04.10.22
-4.62%
16.10.21

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
buy
Valneva SE

Start price
Target price
Perf. (%)
€12.95
03.10.21
€20.00
03.10.22
15.83%
16.10.21

Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
buy
THC Biomed International Inc.

Start price
Target price
Perf. (%)
€0.070
17.04.20
-
04.11.21
-21.43%
14.10.21

Chemocentryx Inc.

Start price
Target price
Perf. (%)
€12.50
30.07.21
€10.00
30.07.22
142.00%
13.10.21

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
buy
Flexion Therapeutics Inc.

Start price
Target price
Perf. (%)
€5.40
29.09.21
€10.00
31.12.24
43.52%
11.10.21

Could be very worthwhile Investment >20% year
Poxel S.A.

Start price
Target price
Perf. (%)
€6.46
06.09.21
€5.00
06.09.22
-9.30%
07.10.21

Could be worthwhile Investment >10% per year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€3.50
14.09.21
-
14.09.22
-30.29%
05.10.21

Innovative
buy
Formycon AG

Start price
Target price
Perf. (%)
€60.40
18.01.21
€80.00
18.01.22
-9.93%
04.10.21

Could be worthwhile Investment >10% per year
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€19.92
28.09.21
-
28.09.22
-6.85%
02.10.21

Could be worthwhile Investment >10% per year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.46
30.09.21
-
30.09.22
0.00%
02.10.21

Risky Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.84
20.09.21
€4.00
20.09.22
-13.38%
02.10.21

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
Innate Pharma

Start price
Target price
Perf. (%)
€6.61
18.09.21
€3.00
18.09.22
-22.01%
02.10.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€5.20
18.09.21
€2.00
18.09.22
-22.69%
02.10.21

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€5.55
20.09.21
€4.00
20.09.22
-13.87%
30.09.21

Good culture
Probably not worthwhile Investment
Below average Management
Little innovation
Editas Medicine Inc

Start price
Target price
Perf. (%)
€46.67
29.09.21
€35.00
31.10.22
-16.73%
29.09.21

Could be very worthwhile Investment >20% year
buy
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€5.50
20.09.21
-
20.09.22
29.09%
21.09.21

Could be worthwhile Investment >10% per year
buy
Adaptimmune Therapeutics PLC ADR

Start price
Target price
Perf. (%)
€4.48
14.09.21
-
14.09.22
-4.46%
19.09.21

Risky Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.94
15.09.21
-
15.09.22
0.00%
19.09.21

Risky Investment
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€3.00
17.09.21
-
17.09.22
73.33%
19.09.21

Risky Investment
buy
Editas Medicine Inc

Start price
Target price
Perf. (%)
€58.60
05.09.21
€70.00
05.09.22
-8.43%
18.09.21

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Good rating
Very low/no dividend yield expected
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€4.42
04.09.21
€2.00
04.09.22
-33.48%
18.09.21

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected